Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study.
J Neurol
; 249(12): 1717-22, 2002 Dec.
Article
em En
| MEDLINE
| ID: mdl-12529796
We assessed safety and efficacy of creatine monohydrate (Cr) in myotonic dystrophy (DM1) in a double-blind, cross-over trial. Thirty-four patients with defined DM1 were randomized to receive Cr and placebo for eight weeks (10.6 g day 1-10, 5.3 g day 11-56) in one of 2 treatment sequences. There was no significant improvement using manual and quantitative muscle strength, daily-life activities, and patients' own global assessment comparing verum with placebo administration. Cr supplementation was well tolerated without clinically relevant side effects, but did not result in significant improvement of muscle strength or daily-life activities.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Creatina
/
Distrofia Miotônica
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Neurol
Ano de publicação:
2002
Tipo de documento:
Article
País de afiliação:
Alemanha